Core Viewpoint - The resignation of Zhang Li as the chairman of Huaren Pharmaceutical is due to personal reasons and is not related to the company's operations or business [1] Group 1 - Huaren Pharmaceutical's board of directors received the resignation report from chairman Zhang Li on August 26 [1] - The company has appointed director Hou Ruipeng to act as the chairman and legal representative temporarily [1] - The company will expedite the process of electing a new chairman in accordance with relevant regulations [1] Group 2 - The decision regarding Zhang Li is linked to a monitoring decision from the Zhouzhi County Public Security Bureau, which is personal and unrelated to the company [1]

华仁药业2024年年报显示，张力出生于1989年2月，硕士研究生学历，特许金融分析师（CFA）。曾任 平安银行股份有限公司金融市场部产品经理、西安曲江崇安私募基金管理有限公司总经理，现任西安曲 江文化金融控股（集团）有限公司总经理助理，兼任西安曲江金控实业投资（集团）有限公司董事长兼 总经理，华仁药业董事。 华仁药业创建于1998年5月，业务聚焦肾科、呼吸科、精麻科及大容量制剂等领域。2024年年报显示， 其实际控制人为西安曲江新区管理委员会。（每经综合，德塔） 【#上市药企36岁董事长被监视居住#】8月26日，华仁药业(300110.SZ)公告称，公司董事会于近日收到 公司董事长张力的辞职报告，张力因个人原因申请辞去公司第八届董事会董事长、法定代表人等相关职 务。 公司于近日收到周至县公安局《监视居住决定书》，上述事项系针对公司董事长张力个人，与公司及相 关业务无任何关联。 公司已推举董事侯瑞鹏代行董事长职责，并计划尽快完成董事长的补选工作。 ...

华仁药业表示，公司于近日收到周至县公安局《监视居住决定书》，上述事项系针对公司董事长张力个 人，与公司及相关业务无任何关联。公司于8月24日召开第八届董事会第十次（临时）会议，同意推举 公司董事侯瑞鹏代行董事长、法定代表人。公司将根据相关规定，按照法定程序尽快完成公司董事长补 选工作。 北京商报讯（记者 丁宁）8月26日晚间，华仁药业（300110）发布公告称，公司董事会于近日收到公司 董事长张力的辞职报告，张力因个人原因申请辞去公司第八届董事会董事长、法定代表人等相关职务。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）董事会于近日收到公司董事长 张力先生的辞职报告，张力先生因个人原因申请辞去公司第八届董事会董事长、 法定代表人等相关职务。 公司于近日收到周至县公安局《监视居住决定书》，上述事项系针对公司董 事长张力先生个人，与公司及相关业务无任何关联。 公司于2025年8月24日召开第八届董事会第十次（临时）会议，同意推举公 司董事侯瑞鹏先生代行董事长、法定代表人。公司将根据相关规定，按照法定程 序尽快完成公司董事长补选工作。 证券代码：300110 证券简称：华仁药业 公告编号：2025-056 华仁药业股份有限公司 重大事项公告 特此公告。 华仁药业股份有限公司董事会 二〇二五年八月二十六日 公司指定信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证 券日报》和巨潮资讯网（http://www.cninfo.com.cn），公司所有信息均以上述指 定媒体刊登的公告为准。敬请广大投资者理性投资，注意投资风险。 ...

证券代码：300110 证券简称：华仁药业 公告编号：2025-055 （一）审议通过《关于推举公司董事代行董事长、法定代表人职责的议案》 经审议，鉴于公司董事长张力先生辞去公司第八届董事会董事长、非独立董 事、第八届董事会战略委员会主任委员职务以及公司法定代表人职务，新任董事 长的选举工作尚需经过相应的法定程序，为保证公司董事会良好运作及公司经营 管理活动的顺利开展，保障公司及股东的合法权益，同意推举公司董事侯瑞鹏先 生代行董事长、法定代表人职责及董事会战略委员会主任委员职责。代行职责的 期限自公司董事会审议通过之日起至董事会选举产生新任董事长之日止。具体内 容详见公司同日披露在中国证监会指定创业板信息披露网站巨潮资讯网的《重大 事项公告》（公告编号：2025-056）。 表决结果：赞成 8 票，反对 0 票，弃权 0 票，获得通过。 三、备查文件 华仁药业股份有限公司 第八届董事会第十次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载，误导性陈述或重大遗漏。 一、董事会会议召开情况 华仁药业股份有限公司（以下简称"公司"）第八届董事会第十次（临时）会 议于 2 ...

Market Overview - As of 13:59, the Shanghai Composite Index is at 3723.60 points, with a decline of 0.12% [1] - The total trading volume of A-shares today is 21,733.08 billion yuan [1] Moving Average Analysis - 26 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yangzi New Materials: 5-day MA is 1.11% lower than the 10-day MA [1] - Ningbo Fanzheng: 5-day MA is 0.94% lower than the 10-day MA [1] - China Petroleum: 5-day MA is 0.40% lower than the 10-day MA [1] Individual Stock Performance - Yangzi New Materials (002652): Today's change is +0.52%, with a 5-day MA of 3.91 yuan and a 10-day MA of 3.95 yuan, showing a distance of -1.11% [1] - Ningbo Fanzheng (300998): Today's change is -1.59%, with a 5-day MA of 25.04 yuan and a 10-day MA of 25.28 yuan, showing a distance of -0.94% [1] - China Petroleum (601857): Today's change is -0.58%, with a 5-day MA of 8.62 yuan and a 10-day MA of 8.66 yuan, showing a distance of -0.40% [1] Additional Stock Insights - Huabei Pharmaceutical (600812): No change today, with a 5-day MA of 6.67 yuan and a 10-day MA of 6.69 yuan, showing a distance of -0.28% [1] - ST Modern (002656): No change today, with a 5-day MA of 2.27 yuan and a 10-day MA of 2.28 yuan, showing a distance of -0.26% [1] - TBEA (600089): Today's change is -0.81%, with a 5-day MA of 13.52 yuan and a 10-day MA of 13.55 yuan, showing a distance of -0.24% [1]

Core Viewpoint - Huaren Pharmaceutical (300110.SZ) reported a significant decline in its financial performance for the first half of 2025, with revenue dropping by 19.13% year-on-year to 624 million yuan and net profit nearly halving to 37.33 million yuan, primarily due to the impact of centralized procurement and an imbalanced product structure [1] Revenue Breakdown - Revenue from basic infusion products decreased by 38.86% to 253 million yuan [1] - Revenue from therapeutic preparations fell by 9.71% [1] - Despite a 45.80% increase in sales volume, the revenue from peritoneal dialysis fluid rose to 218 million yuan, but the bidding price was significantly low at 14.83 yuan per bag [1] - Revenue from medical devices declined by 19.34% to 50.77 million yuan [1] Shareholder Activity - The second-largest shareholder, Huaren Century Group Co., Ltd., reduced its holdings by 11.82 million shares in July 2025, amounting to approximately 40 million yuan, decreasing its stake to 6.9% [1] - The third-largest shareholder, Hongta Innovation, also reduced its holdings by 11.82 million shares in April 2025, with a transaction value of about 39.11 million yuan, lowering its stake to 5.72% [1]

据iFind统计，截至8月15日，沪深两市共有163只个股连续5日或5日以上获融资净买入。连续获融资净 买入天数最多的股票是惠城环保，已连续25个交易日获净买入；连续获融资净买入天数较多的还有华曙 高科、景嘉微、凯盛新材、淳中科技、涪陵电力、诺瓦星云、博威合金、振华风光、美埃科技、华仁药 业等股，分别获14个、13个、12个、10个、10个、10个、10个、9个、9个、9个交易日净买入。 （文章来源：证券时报网） ...

Financial Performance - Huaren Pharmaceutical reported a net profit decrease of 49.01% for the first half of 2025, with total revenue of 624 million yuan, down 19.13% year-on-year [1] - The company's gross profit margin was 37.73%, a slight decrease of 0.06% compared to the previous year, while the net profit margin fell significantly by 36.87% to 6.28% [1] - Total expenses (selling, administrative, and financial) amounted to 151 million yuan, representing 24.24% of revenue, an increase of 19.08% year-on-year [1] Key Financial Metrics - Earnings per share (EPS) dropped to 0.03 yuan, a decline of 48.95% year-on-year, while the net asset per share decreased by 51.21% to 1.13 yuan [1] - The company reported a cash flow per share of 0.14 yuan, which remained stable with a year-on-year increase of 5.29% [1] - The company's return on invested capital (ROIC) over the past decade has been weak, with a median of 3.08% and a particularly poor ROIC of -34.45% in 2024 [3] Business Model and Operational Insights - The company's performance is primarily driven by marketing efforts, necessitating a thorough examination of the underlying factors influencing this drive [3] - Historical financial data indicates that the company has had a generally poor financial performance, with one loss year out of 14 annual reports since its listing [3] - The cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 14.42%, and the average operating cash flow to current liabilities ratio at 19.26% over the past three years [3]

Core Viewpoint - The company reported a loss for the fiscal year 2024 and will not distribute cash dividends, issue bonus shares, or increase capital from reserves [5]. Company Overview - The company has not changed its controlling shareholder or actual controller during the reporting period [5]. - The company has no preferred shareholders or related shareholding situations during the reporting period [5]. Financial Data and Indicators - The company plans to apply for a total credit limit of up to RMB 3.91 billion from various banks to meet operational and business development needs [6]. - The company will provide a joint liability guarantee of up to RMB 1 billion for its subsidiaries, while subsidiaries will provide a guarantee of up to RMB 2.5 billion for the company [6]. Important Matters - The company has fully provided for credit impairment losses on receivables from a subsidiary, Qingdao Huarun Pharmaceutical Co., Ltd., due to a debt resolution framework with Guoyao Medicinal Materials Co., Ltd. [7]. - The execution of the debt resolution framework remains uncertain, and the company is actively following up to maximize recovery of losses [7].